Basic Information
| LncRNA/CircRNA Name | Metalnc9 |
| Synonyms | LINC00963 |
| Region | GRCh38_9:129483451-129513686 |
| Ensemble | ENSG00000204054 |
| Refseq | NR_038955 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Northern blot, RIP etc. |
| Sample | cell lines (H1299, H292 ) |
| Expression Pattern | up-regulated |
| Function Description | Elevated expression of LINC00963 (MetaLnc9) in human NSCLC specimens correlated with poor prognosis, promoted migration and invasion of NSCLC cells in vitro, and enhanced lung metastasis formation in vivo. Mechanistic investigations showed that MetaLnc9 interacted with the glycolytic kinase PGK1 and prevented its ubiquitination in NSCLC cells, leading to activation of the oncogenic AKT/mTOR signaling pathway. MetaLnc9 also interacted with P54nrb/NonO (NONO) to help mediate the activity of CRTC, a co-activator for the transcription factor CREB, reinforcing a positive feedback loop for metastasis. Taken together, our results establish MetaLnc9 as a driver of metastasis and a candidate therapeutic target for treating advanced NSCLC. |
| Pubmed ID | 28923857 |
| Year | 2017 |
| Title | MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway |
External Links
| Links for Metalnc9 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |